Prognostic Role of Inflammatory Indices and Real-World Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine
Diagnostics · 05.06.2026 · 16 (11) · 1746
DOI: 10.3390/diagnostics16111746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 05.06.2026. Verfasst von Taliha Güçlü Kantar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Denizli State Hospital, Denizli 20070, Türkiye. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: Reliable pretreatment biomarkers to guide treatment selection in HER2-positive metastatic breast cancer (mBC) remain an unmet need. Systemic inflammatory indices derived from routine blood tests have emerged as accessible prognostic markers. This study evaluated the prognostic value of inflammation-based indices in patients with HER2-positive mBC treated with trastuzumab emtansine (T-DM1). Materials and Methods: In this retrospective single-center cohort study, 50 patients with HER2-positive mBC treated with T-DM1 in the second-line setting were analyzed. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method. ROC analysis assessed the prognostic performance of the CRP/albumin ratio (CAO), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). Variables associated with PFS were further evaluated using multivariable Cox regression.
Results
The median follow-up was 46 months. Median OS from initial diagnosis and median PFS from T-DM1 initiation were 96 and 7 months, respectively. Metastatic pattern (p = 0.010), CNS involvement at T-DM1 initiation (p = 0.025), liver metastasis (p = 0.041), and best radiologic response (p < 0.001) were associated with PFS. ROC analysis showed modest discrimination (CAO AUC 0.694, NLR 0.658, PLR 0.646, and SII 0.653). In multivariable analysis, best radiologic response to T-DM1 was strongly associated with progression risk and appeared to reflect treatment sensitivity rather than acting as a pretreatment predictor.
Conclusions
T-DM1 provided meaningful disease control in this real-world cohort. Treatment response was the main determinant of progression, while baseline inflammatory markers offered modest complementary prognostic value. These findings may aid patient selection for T-DM1, particularly in settings with limited access to trastuzumab deruxtecan.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Denizli State Hospital, Denizli 20070, Türkiye.
- Department of Medical Oncology, School of Medicine, Pamukkale University, Denizli 20070, Türkiye.
- Department of Nuclear Medicine, School of Medicine, Pamukkale University, Denizli 20070, Türkiye.
- Department of Medical Oncology, School of Medicine, Muğla University, Mugla 48000, Türkiye.
ORCID-Profile: Taliha Güçlü Kantar, Tolga Doğan, Bedriye Açıkgöz Yıldız, Gamze Serin Özel, Ceren Mordağ Çiçek, Tarık Şengöz, Özgür Tanrıverdi
Zitieren
APA
Güçlü Kantar, T., Doğan, T., Taş, S., Açıkgöz Yıldız, B., Serin Özel, G., Çiçek, C. M., Kantar, A. A., Yapar Taşköylü, B., Demiray, A. G., Şengöz, T., Tanrıverdi, Ö., Yaren, A., & Gököz Doğu, G. (2026). Prognostic Role of Inflammatory Indices and Real-World Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine. Diagnostics, 16(11), 1746. https://doi.org/10.3390/diagnostics16111746
Vancouver
Güçlü Kantar T, Doğan T, Taş S, Açıkgöz Yıldız B, Serin Özel G, Çiçek CM, et al. Prognostic Role of Inflammatory Indices and Real-World Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine. Diagnostics. 2026;16(11):1746. doi:10.3390/diagnostics16111746
BibTeX
@article{GlKantar2026,
author = {Güçlü Kantar, Taliha and Doğan, Tolga and Taş, Semra and Açıkgöz Yıldız, Bedriye and Serin Özel, Gamze and Çiçek, Ceren Mordağ and Kantar, Ahmet Ali and Yapar Taşköylü, Burcu and Demiray, Atike Gökçen and Şengöz, Tarık and Tanrıverdi, Özgür and Yaren, Arzu and Gököz Doğu, Gamze},
title = {Prognostic Role of Inflammatory Indices and Real-World Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {11},
pages = {1746},
doi = {10.3390/diagnostics16111746}
}
EUVIMED